Director/PDMR Shareholding

RNS Number : 2402C

Synairgen plc

15 October 2020

 

Synairgen plc

("Synairgen" or the "Company")

Director Dealing/PDMR Announcement

Further to the announcement earlier today regarding the Placing, the Company makes the below announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014) in respect of the exercise of options by Richard Marsden, CEO of the Company, and John Ward, Finance Director of the Company.

Enquiries:

Synairgen plc                                                                                                      [phone]

Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)

finnCap - Nominated Adviser and Joint Bookrunner                                [phone]

Geoff Nash / James Thompson / Charlie Beeson (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

Numis - Joint Bookrunner                                                                                [phone]

James Black / Freddie Barnfield / Duncan Monteith

Consilium Strategic Communications - Financial Media and Investor  [phone]

Relations Adviser

Mary-Jane Elliott / Sue Stuart / Olivia Manser

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	R ichard Marsden
2.	Reason for notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	O ptions over o rdinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Exercise of options over Ordinary Shares
c)	Price(s) and volume(s)	386,842 Ordinary shares of 1p each
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	15 October 2020
f)	Place of the transaction	London Stock Exchange

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	John Ward
2.	Reason for notification
a)	Position / status	Finance Director
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	O ptions over o rdinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Exercise of options over Ordinary Shares
c)	Price(s) and volume(s)	147,330 Ordinary shares of 1p each
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	15 October 2020
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHEAAESFLNEFFA